{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:14:44Z","timestamp":1793812484348,"version":"4.6.1"},"reference-count":22,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Determination of measurable residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL) using next-generation immunosequencing (clonoSEQ; Adaptive Biotechnologies) has emerged as an essential and sensitive tool. The clonoSEQ assay identifies and tracks all the B-cell and T-cell receptor rearrangements present in a sample. With widening clinical use of immunosequencing for MRD monitoring (next-generation sequencing [NGS]-MRD), clinicians are increasingly encountering cases with results that are considered to be inconclusive, where immunosequencing yields detectable clonotypic sequences, yet it is unclear whether they indicate ALL, normal background, or an independent etiology. There is a need for guidance in the clinical interpretation of immunosequencing results. In this article, we describe various features of immunosequencing reporting and their clinical implications through a series of illustrative clinical cases. Each case presents a distinct scenario encountered in the clinical setting where NGS-MRD had varying clinical implications. Through aggregate evaluation of the various components of the results, such as the sequence locus, sequence abundance, clonal tracking, and levels of detection and blank, we formulate systematic interpretative tools that can be leveraged to inform clinical decision-making. The goal of this article is to serve as a useful guide for clinicians as they interpret immunosequencing results for pediatric ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018923","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:46:28Z","timestamp":1772138788000},"page":"3281-3289","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Interpreting next-generation immunosequencing results in children and young adults with acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2308-4425","authenticated-orcid":false,"given":"Rohaum","family":"Hamidi","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5592-5201","authenticated-orcid":false,"given":"Ilan","family":"Kirsch","sequence":"additional","affiliation":[{"name":"2Adaptive Biotechnologies, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-7597","authenticated-orcid":false,"given":"Liora","family":"Schultz","sequence":"additional","affiliation":[{"name":"3Pediatric Hematology\/Oncology and Cellular Immunotherapy, Columbia University School of Medicine, New York City, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"3","key":"2026051211213061700_bib1","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1002\/cpz1.383","article-title":"Measurable residual disease detection in B-acute lymphoblastic leukemia: the Children\u2019s Oncology Group (COG) method","volume":"2","author":"Borowitz","year":"2022","journal-title":"Curr Protoc"},{"issue":"4","key":"2026051211213061700_bib2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.5858\/arpa.2020-0457-OA","article-title":"Assessment of clonotypic rearrangements and minimal residual disease in lymphoid malignancies","volume":"146","author":"Hussaini","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2026051211213061700_bib3","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"12","key":"2026051211213061700_bib4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026051211213061700_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/14737159.2019.1627877","article-title":"ClonoSEQ assay for the detection of lymphoid malignancies","volume":"19","author":"Monter","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"issue":"10","key":"2026051211213061700_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"issue":"22","key":"2026051211213061700_bib7","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.2019001077","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2026051211213061700_bib8","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1182\/blood-2021-152369","article-title":"Performance of next generation sequencing for minimal residual disease detection for pediatric patients with acute lymphoblastic leukemia: results from the prospective clinical trial DFCI 16-001","volume":"138","author":"Paolino","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2026051211213061700_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute lymphoblastic leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2026051211213061700_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.coi.2009.03.009","article-title":"Mechanics of T cell receptor gene rearrangement","volume":"21","author":"Krangel","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"2026051211213061700_bib11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.leukres.2005.11.007","article-title":"The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression","volume":"30","author":"Meleshko","year":"2006","journal-title":"Leuk Res"},{"issue":"3","key":"2026051211213061700_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.2023023699","article-title":"How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL","volume":"144","author":"Muffly","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026051211213061700_bib13","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbmt.2014.04.018","article-title":"Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival","volume":"20","author":"Logan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026051211213061700_bib14","doi-asserted-by":"crossref","first-page":"8091746","DOI":"10.1155\/2022\/8091746","article-title":"Concordance of peripheral blood and bone marrow next-generation sequencing in hematologic neoplasms","volume":"2022","author":"Jumniensuk","year":"2022","journal-title":"Adv Hematol"},{"issue":"1","key":"2026051211213061700_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2026051211213061700_bib16","doi-asserted-by":"publisher","DOI":"10.1101\/2024.03.26.583354","article-title":"Identifying immune signatures of common exposures through co-occurrence of T-cell receptors in tens of thousands of donors","author":"May","year":"27, 2024","journal-title":"bioRxiv"},{"issue":"suppl 1","key":"2026051211213061700_bib17","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1182\/blood-2023-190624","article-title":"Next-generation sequencing (NGS) for residual disease (MRD) monitoring in T-lymphoblastic leukemia (T-ALL)","volume":"142","author":"Roy","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026051211213061700_bib18","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3390\/cancers14081873","article-title":"Early T-cell precursor ALL and beyond: immature and ambiguous lineage T-ALL subsets","volume":"14","author":"Genesc\u00e0","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"2026051211213061700_bib19","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1182\/blood-2021-152369","article-title":"Performance of next generation sequencing for minimal residual disease detection for pediatric patients with acute lymphoblastic leukemia: results from the prospective clinical trial DFCI 16-001","volume":"138","author":"Paolino","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2026051211213061700_bib20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/bloodadvances.2023011997","article-title":"Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas","volume":"8","author":"Shukla","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2026051211213061700_bib21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3109\/07357907.2011.584587","article-title":"Analysis of somatic hypermutations of immunoglobulin gene rearrangements in childhood acute lymphoblastic leukemia","volume":"29","author":"Braoudaki","year":"2011","journal-title":"Cancer Invest"},{"issue":"10","key":"2026051211213061700_bib22","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/leu.2012.246","article-title":"EuroClonality\/BIOMED-2 guidelines for interpretation and reporting of Ig\/TCR clonality testing in suspected lymphoproliferations","volume":"26","author":"Langerak","year":"2012","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3281\/2518830\/blooda_adv-2025-018923-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3281\/2518830\/blooda_adv-2025-018923-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:21:41Z","timestamp":1778599301000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3281\/566868\/Interpreting-next-generation-immunosequencing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018923","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,5,12]]}}}